Brokerages Anticipate Pyxis Oncology, Inc. (NASDAQ:PYXS) Will Post Earnings of -$0.62 Per Share

Wall Street analysts expect that Pyxis Oncology, Inc. (NASDAQ:PYXSGet Rating) will report ($0.62) earnings per share (EPS) for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Pyxis Oncology’s earnings, with the highest EPS estimate coming in at ($0.43) and the lowest estimate coming in at ($0.73). The firm is scheduled to issue its next earnings results on Monday, January 1st.

On average, analysts expect that Pyxis Oncology will report full-year earnings of ($2.83) per share for the current fiscal year, with EPS estimates ranging from ($3.72) to ($1.96). For the next fiscal year, analysts expect that the business will report earnings of ($2.69) per share, with EPS estimates ranging from ($3.49) to ($2.18). Zacks’ EPS averages are an average based on a survey of analysts that follow Pyxis Oncology.

Separately, Zacks Investment Research upgraded shares of Pyxis Oncology from a “sell” rating to a “hold” rating in a research note on Tuesday, January 18th. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $20.00.

Institutional investors and hedge funds have recently made changes to their positions in the company. Citigroup Inc. acquired a new position in shares of Pyxis Oncology during the 4th quarter worth $35,000. California State Teachers Retirement System acquired a new position in Pyxis Oncology in the 4th quarter valued at $64,000. New York State Common Retirement Fund acquired a new position in Pyxis Oncology in the 4th quarter valued at $69,000. Davidson Kempner Capital Management LP acquired a new position in Pyxis Oncology in the 4th quarter valued at $109,000. Finally, Sandia Investment Management LP acquired a new position in Pyxis Oncology in the 4th quarter valued at $110,000. Institutional investors own 18.76% of the company’s stock.

Pyxis Oncology stock opened at $3.65 on Tuesday. The company has a 50 day moving average of $5.42. Pyxis Oncology has a twelve month low of $3.25 and a twelve month high of $19.00.

About Pyxis Oncology (Get Rating)

Pyxis Oncology, Inc, a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors; and PYX-102, an investigational immune-therapeutic for treatment of solid tumors.

Featured Articles

Get a free copy of the Zacks research report on Pyxis Oncology (PYXS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Pyxis Oncology (NASDAQ:PYXS)

Receive News & Ratings for Pyxis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pyxis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.